Cost-effectiveness of single, high-dose, liposomal amphotericin regimen for HIV-associated cryptococcal meningitis in five countries in sub-Saharan Africa: an economic analysis of the AMBITION-cm trial
| dc.contributor.author | Lawrence, David S. | |
| dc.contributor.author | Tugume, Lillian | |
| dc.contributor.author | Mwandumba, Henry C. | |
| dc.contributor.author | Kanyama, Cecilia | |
| dc.contributor.author | Muzoora, Conrad | |
| dc.contributor.author | Nuwagira, Edwin | |
| dc.contributor.author | Niessen, Louis W. | |
| dc.date.accessioned | 2025-04-03T14:39:05Z | |
| dc.date.available | 2025-04-03T14:39:05Z | |
| dc.date.issued | 2022-12-01 | |
| dc.description.abstract | HIV-associated cryptococcal meningitis is a leading cause of AIDS-related mortality. The AMBITION-cm trial showed that a regimen based on a single high dose of liposomal amphotericin B deoxycholate (AmBisome group) was non-inferior to the WHO-recommended treatment of seven daily doses of amphotericin B deoxycholate (control group) and was associated with fewer adverse events. We present a five-country cost-effectiveness analysis. | |
| dc.identifier.citation | Lawrence, D. S., Muthoga, C., Meya, D. B., Tugume, L., Williams, D., Rajasingham, R., ... & Kufa, P. (2022). Cost-effectiveness of single, high-dose, liposomal amphotericin regimen for HIV-associated cryptococcal meningitis in five countries in sub-Saharan Africa: an economic analysis of the AMBITION-cm trial. The Lancet Global Health, 10(12), e1845-e1854. | |
| dc.identifier.issn | 1845-e1854 | |
| dc.identifier.uri | https://nru.uncst.go.ug/handle/123456789/10349 | |
| dc.language.iso | en | |
| dc.publisher | The Lancet Global Health | |
| dc.title | Cost-effectiveness of single, high-dose, liposomal amphotericin regimen for HIV-associated cryptococcal meningitis in five countries in sub-Saharan Africa: an economic analysis of the AMBITION-cm trial | |
| dc.type | Article |